A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.

被引：0
|
作者：
Smith, Alan D.
Chan, Kelvin K.
Lim, Howard John
Cheung, Winson Y.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Princess Margaret Hosp, Sunnybrook Odette Canc Ctr, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14532
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼
    Ogawa, Chikara
    Morita, Masahiro
    Omura, Akina
    Shibatoge, Mitsushige
    Tsutsui, Akemi
    Senoh, Tomonori
    Nagano, Takuya
    Takaguchi, Kouichi
    Tani, Joji
    Morishita, Asahiro
    Yoneyama, Hirohito
    Masaki, Tsutomu
    Moriya, Akio
    Ando, Masaharu
    Deguchi, Akihiro
    Kudo, Masatoshi
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [43] Myopenia as a significant prognostic factor in BCLC-B intermediate-stage hepatocellular carcinoma treated with sorafenib.
    Okada, Mao
    Nakanishi, Hiroyuki
    Kurosaki, Masayuki
    Kirino, Sakura
    Osawa, Leona
    Watakabe, Keiya
    Wang, Wan
    Shimizu, Takao
    Takaura, Kenta
    Takada, Hitomi
    Kaneko, Shun
    Tamaki, Nobuharu
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Itakura, Jun
    Takahashi, Yuka
    Izumi, Namiki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] The prognostic markers in hepatocellular carcinoma treated with sorafenib
    Kawasaki, Takeshi
    Tokunaga, Takayuki
    Fujie, Satomi
    Yoshimaru, Yoko
    Watanabe, Takehisa
    Setoyama, Hiroko
    Tateyama, Masakuni
    Tanaka, Motohiko
    Sasaki, Yutaka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 419 - 419
  • [45] Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography
    Moschouris, Hippocrates
    Malagari, Katerina
    Gkoutzios, Panagiotis
    Kalokairinou, Marianna
    Stamatiou, Konstantinos
    Chatzimichail, Katerina
    Kornezos, Ioannis
    Karagiannis, Evagelos
    Kiltenis, Michail
    Papadaki, Marina Georgiou
    MEDICAL ULTRASONOGRAPHY, 2012, 14 (02) : 87 - 94
  • [46] Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
    Meyers, Daniel E.
    Lee-Ying, Richard M.
    Alghamdi, Mohammed Abdullah
    Cheung, Winson Y.
    Samawi, Haider
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database
    Samawi, H. H.
    Hao-Wen, S.
    Chan, K.
    Alghamdi, M. A.
    Lee-Ying, R. M.
    Knox, J.
    Gill, P.
    Romagnino, A.
    Batuyong, E.
    Ko, Y-J.
    Cheung, W. Y.
    Tam, V. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis
    Liu, Lixing
    Gong, Yang
    Zhang, Qinglin
    Cai, Panpan
    Feng, Li
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [49] Japan multicenter prospective study: FDG PET/CT in the assessment of advanced renal cell carcinoma treated with sorafenib.
    Nakaigawa, Noboru
    Tateishi, Ukihide
    Kato, Takuma
    Kaneta, Tomohiro
    Kondo, Keiichi
    Sugimoto, Mikio
    Yao, Masahiro
    Inoue, Tomio
    Kakehi, Yoshiyuki
    Kubota, Yoshinobu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib
    Okuyama, Hiroyuki
    Ikeda, Masafumi
    Kuwahara, Akiko
    Takahashi, Hideaki
    Ohno, Lzumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Senda, Shoichi
    Okusaka, Takuji
    ONCOLOGY, 2015, 88 (04) : 241 - 246
12345